Researchers at the University of Pennsylvania have created a gene therapy that acts as a precise "off switch" for chronic pain in the brain, without triggering the addictive reward pathways that make opioids so dangerous. Published in Nature on March 28, the therapy uses AI-driven behavioral tracking to map how pain is processed in cortical circuits, then delivers a targeted intervention that mimics morphine's analgesic benefits while skipping its side effects.

Lead researcher Gregory Corder, assistant professor of psychiatry and neuroscience at Penn, called it "the world's first CNS-targeted gene therapy for pain and a concrete blueprint for non-addictive, circuit-specific pain medicine." The six-year project, funded by an NIH New Innovator Award, involved collaborators from Carnegie Mellon University and Stanford University.

The breakthrough addresses a massive public health crisis: over 50 million Americans live with chronic pain, costing more than $635 billion annually, while opioids were involved in 80% of 600,000 drug-related deaths in 2019 alone.